A Phase 1/2, First-in-Human, Multicenter, Ascending Single-Dose and Multi-Dose Study to Assess the Safety of DIAG723, a Novel Bispecific ALK-1 and BMPRII Agonist Antibody in Adult Patients with Hereditary Hemorrhagic Telangiectasia (DIAMOND trial)
Condition studied
Hereditary Hemorrhagic Telangiectasia (HHT)
Investigational medicinal product(s)
Eligibility
Primary endpoint
Incidence, nature, severity, and relationship of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs) following administration of DIAG723., Changes from baseline in clinical laboratory parameters, vital signs, physical examination findings, and electrocardiogram (ECG) parameters.
Endpoint detail
Pharmacokinetic parameters of DIAG723, including maximum observed concentration (Cmax), time to maximum concentration (Tmax), area under the concentration-time curve (AUC), trough concentration (Ctrough), terminal half-life (t½), apparent clearance (CL/F), and apparent volume of distribution (Vz/F)., Incidence and magnitude of anti-drug antibodies (ADAs) and neutralizing antibodies to DIAG723., Changes from baseline in epistaxis frequency, duration, and severity., Changes from baseline in hemoglobin levels and other hematologic parameters., Changes in transfusion requirements and iron supplementation requirements., Changes in arteriovenous malformation (AVM)-related assessments and exploratory biomarkers of target engagement and pharmacodynamic activity., Changes from baseline in patient-reported outcomes and health-related quality of life measures.
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View 2026-526271-29-00 on CTIS ↗ ← All trials in the EU